Search research articles
Contact Us
Filters
Showing results (1-10 of 28) with videos related to
Page
of 3
Sort By:
Risk Analysis : an Official Publication of the Society for Risk Analysis
|
June 24, 2004
Mad cow hysteria
David W Gaylor
Risk Analysis : an Official Publication of the Society for Risk Analysis
|
March 25, 2005
Risk/benefit assessments of human diseases: optimum dose for intervention
David W Gaylor
Regulatory Toxicology and Pharmacology : RTP
|
February 9, 2005
Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
David W Gaylor
Risk Analysis : an Official Publication of the Society for Risk Analysis
|
January 18, 2003
Commentary on the conference on decision-making under conditions of uncertainty for rare diseases
David W Gaylor
Risk Analysis : an Official Publication of the Society for Risk Analysis
|
January 22, 2005
Role of the standard deviation in the estimation of benchmark doses with continuous data
David W Gaylor, William Slikker
Regulatory Toxicology and Pharmacology : RTP
|
July 22, 2004
An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD)
David W Gaylor, Lesa L Aylward
Regulatory Toxicology and Pharmacology : RTP
|
June 8, 2002
A procedure for developing risk-based reference doses
David W Gaylor, Ralph L Kodell
Chemical Research in Toxicology
|
April 24, 2008
Dose-response relationships for cancer incidence reflect susceptibility distributions
Werner K Lutz, David W Gaylor
Mutation Research
|
July 13, 2002
Statistical calculation of detection limits for DNA adducts using the 32P-postlabeling assay with a standard addition procedure
Werner K Lutz, Ursula Lutz, David W Gaylor
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 23, 2003
Thresholds of carcinogenicity in the ED01 study
Melvin E Andersen, Rory B Conolly, David W Gaylor
Page
of 3
Search research articles
Search
Showing results (1-10 of 28) with videos related to
Sort By:
Page
of 3
Risk Analysis : an Official Publication of the Society for Risk Analysis
|
June 24, 2004
Mad cow hysteria
David W Gaylor
Risk Analysis : an Official Publication of the Society for Risk Analysis
|
March 25, 2005
Risk/benefit assessments of human diseases: optimum dose for intervention
David W Gaylor
Regulatory Toxicology and Pharmacology : RTP
|
February 9, 2005
Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
David W Gaylor
Risk Analysis : an Official Publication of the Society for Risk Analysis
|
January 18, 2003
Commentary on the conference on decision-making under conditions of uncertainty for rare diseases
David W Gaylor
Risk Analysis : an Official Publication of the Society for Risk Analysis
|
January 22, 2005
Role of the standard deviation in the estimation of benchmark doses with continuous data
David W Gaylor, William Slikker
Regulatory Toxicology and Pharmacology : RTP
|
July 22, 2004
An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD)
David W Gaylor, Lesa L Aylward
Regulatory Toxicology and Pharmacology : RTP
|
June 8, 2002
A procedure for developing risk-based reference doses
David W Gaylor, Ralph L Kodell
Chemical Research in Toxicology
|
April 24, 2008
Dose-response relationships for cancer incidence reflect susceptibility distributions
Werner K Lutz, David W Gaylor
Mutation Research
|
July 13, 2002
Statistical calculation of detection limits for DNA adducts using the 32P-postlabeling assay with a standard addition procedure
Werner K Lutz, Ursula Lutz, David W Gaylor
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 23, 2003
Thresholds of carcinogenicity in the ED01 study
Melvin E Andersen, Rory B Conolly, David W Gaylor
Page
of 3